Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis
暂无分享,去创建一个
D. Felson | M. LaValley | A. Bujor | J. Durán | S. Janjua | J. Braun | M. Lavalley | Jürgen Braun
[1] G. Agarwal,et al. Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short‐term study , 2016, International journal of rheumatic diseases.
[2] M. Suarez‐Almazor,et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. , 2017, The Cochrane database of systematic reviews.
[3] R. Landewé,et al. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis , 2017, RMD Open.
[4] M. Dougados,et al. 2016 update of the EULAR recommendations for the management of early arthritis , 2016, Annals of the rheumatic diseases.
[5] M. Schiff,et al. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis , 2017, Rheumatology International.
[6] G. Burmester,et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study , 2016, The Lancet.
[7] Zhouyuan Yang,et al. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis. , 2016, Seminars in arthritis and rheumatism.
[8] D. Felson,et al. Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review , 2016, Annals of the rheumatic diseases.
[9] Charles King,et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.
[10] E. Keystone,et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis , 2015, Annals of the rheumatic diseases.
[11] Raveendhara R. Bannuru,et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .
[12] M. Islam,et al. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. , 2013, Mymensingh medical journal : MMJ.
[13] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[14] C. Kelly,et al. When should we use parenteral methotrexate? , 2010, Clinical Rheumatology.
[15] U Pichlmeier,et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. , 2008, Arthritis and rheumatism.
[16] J. Jacobs,et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) , 2007, Annals of the rheumatic diseases.
[17] D. M. van der Heijde,et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. , 2006, Arthritis and rheumatism.
[18] M. A. van de Laar,et al. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. , 2006, The Journal of rheumatology.
[19] F. Breedveld,et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.
[20] M. A. van de Laar,et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. , 2004, The Journal of rheumatology.
[21] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[22] R. Misra,et al. Methotrexate twice weekly vs once weekly in rheumatoid arthritis: a pilot double-blind, controlled study , 2002, Rheumatology International.
[23] S. Gabriel,et al. The epidemiology of rheumatoid arthritis. , 2001, Rheumatic diseases clinics of North America.
[24] Richard W. Martin,et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.
[25] C. Helmick,et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. , 1998, Arthritis and rheumatism.
[26] J. Kremer,et al. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. , 1997, British journal of rheumatology.
[27] D. Furst,et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. , 1989, The Journal of rheumatology.
[28] C. Werning. [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.